Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC

Publication
Article
ONCOLOGY® CompanionONCOLOGY® Companion, Volume 38, Supplement 6
Volume 38
Issue 6
Pages: 12

A recent Training Academy focused on the advancements of treatment for patients with NSCLC EGFR mutations and exon 20 insertions.

Meet the Experts

Meet the Experts

A recent Training Academy focused on the advancements of treatment for patients with non–small cell lung cancer (NSCLC). The panel focused on options for patients with EGFR mutations and exon 20 insertion. Here are their key takeaways in the space.

Biomarker Testing

  • It is based on stage and histology and looks for PD-L1 expression.
    • The focus is on completing next-generation sequencing prior to treatment.
  • Testing helps determine therapy options and which patients are the best candidates for neoadjuvant chemotherapy plus immunotherapy.

Treatment for EGFR-Mutated NSCLC

  • Osimertinib (Tagrisso) monotherapy is considered the standard of care.
    • Treatment is based on results from the phase 3 FLAURA study (NCT02296125).1
  • Afatinib (Gilotrif) package insert is directed for uncommon mutations in NSCLC.2
  • There are no head-to-head data for afatinib vs osimertinib.
    • Physicians should consider patients tolerance and central nervous system penetration for the treatment.

Treatment for Exon 20 Insertion+ NSCLC

  • Amivantamab-vmjw (Rybrevant) plus chemotherapy was approved in March 2024 for patients with exon 20 insertion mutations.3
  • Patients fit enough for chemotherapy should consider this combination because of the compelling efficacy results.
    • Patients with central nervous systemmetastases were excluded from the phase 3 PAPILLON trial (NCT04538664).

Unmet Needs in the Space

  • Advancing risk-adaptive care
    • Focusing on risk stratification and personalized treatment
  • Personalized therapy beyond the first-line setting
    • Performing new biopsies and identifying the mechanism of resistance
  • Evaluating the minimum-tolerated dose vs the maximum-tolerated dose
    • Project Optimus was created by the FDA for this reason.4

References

  1. Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125. doi:10.1056/NEJMoa1713137
  2. Gilotrif. Prescribing information. Boehringer Ingelheim; 2013. Accessed May 6, 2024. https://shorturl.at/kzEGW
  3. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. FDA. March 1, 2024. Accessed May 6, 2024. https://shorturl.at/GJKX9
  4. Project Optimus. FDA. January 5, 2024. Accessed May 6, 2024. https://shorturl.at/dlsEF
Download Issue PDFDownload PDF
Articles in this issue
Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice
Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice
Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC
Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC
Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC
Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC
Recent Videos
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
An intravenous infusion administered prior to surgery enables treatment to occur in a normal time frame without the need for additional procedural time.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Related Content
3 Things You Should Know About Hemolytic Anemias

3 Things You Should Know About Hemolytic Anemias

Catherine M. Broome, MD;Sigbjørn Berentsen, MD, PhD;Caroline Piatek, MD;Ilene Ceil Weitz, MD
December 20th 2024
Article

Hemolytic anemias are a collection of rare but severe diseases including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.

FDA Approves Ensartinib in Metastatic ALK-Positive NSCLC

Roman Fabbricatore
December 18th 2024
Article

Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
December 10th 2024
Article

Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.

Zolbetuximab’s Impact on Gastric/GEJ Adenocarcinoma

Zolbetuximab’s Impact on Gastric/GEJ Adenocarcinoma

ONCOLOGY Staff
December 6th 2024
Article

John Marshall, MD, discussed zolbetuximab, which the FDA recently approved for patients with CLDN18.2–positive locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.